Alzheimer's AAIC Video Interview: Denali Therapeutics

Denali CEO Ryan Watts talks about the company's TransportVehicle platform and how it can open up delivery of a wide range of drug cargoes into the brain. Its first approved therapy is Avlayah for Hunter Syndrome, with tau and beta-amyloid targeting assets for Alzheimer's in development.